Colchicine in patients with chronic inflammatory cardiomyopathy: rationale and design of the CMP-MYTHiC

ESC Heart Failure 2026 Open access

Read full text
Authors: Enrico Ammirati, Iside Cartella, Michele Ciabatti, Giada Colombo, Marco Masetti, Maurizio Pieroni, Guglielmo Gallone, G Peretto, Luciano Potena, R Scacciavillani, Claudia Raineri, Adriano Caputo
+21 more Patrizia Pedrotti, Paola Sormani, Nicolina Conti, Marco Merlo, Massimo Imazio, Arianna Pani, Mirko L Ciliberti, Piero Gentile, Gianluca Pontone, Andrea Villatore, Enrica Pezzullo, Matteo Palazzini, Michela Casella, Maria Grazia Valsecchi, F Burzotta, Veronica Carmina, Andrea Garascia, Antonio Scarale, Davide Paolo Bernasconi, F Loffredo, M L Narducci
DOI: 10.1093/eschf/xvag058
Cited by: 4
References: 55

Abstract

INTRODUCTION: Acute myocarditis can lead to chronic inflammatory cardiomyopathy (Infl-CMP), a condition characterized by increased risk of ventricular arrhythmias (VA), left ventricular (LV) systolic dysfunction (LVSD), and heart failure (HF). Immunosuppressive therapy is generally not recommended for Infl-CMP when diagnosed non-invasively by cardiac magnetic resonance imaging (CMRI) or fluorodeoxyglucose-positron emission tomography (FDG-PET). We are assessing, in the CMP-MYTHiC trial, whether colchicine (0.5 mg in patients

Fields of Study & Subjects

Inflammasome and immune disorders Pericarditis and Cardiac Tamponade Inflammatory Myopathies and Dermatomyositis

Publication details

Journal / source
ESC Heart Failure
Publisher
Oxford University Press (OUP)
Volume
13
Issue
2
Publication date
17 February 2026
Language
EN